Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns

Neonatal sepsis is a leading cause of death for newbornsTesting IL-6 can indicate a neonatal sepsis infection earlier than other biomarkersEarlier diagnosis of neonatal sepsis can lead to improved outcomes and a reduction of long-term complications from sepsisBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries accepting the CE Mark.*Elecsys IL-6 aids physicians in combating the impact of neonatal sepsis by facilitating an early diagnosis. Early and improved diagnosis can contribute to appropriate use of antibiotics, as well as potentially decreasing mortality rates and mitigating long-term consequences of sepsis.“Sepsis is one of the leading causes of death in newborns and we need to do everything we can to prevent these deaths, " said Matt Sause, CEO of Roche Diagnostics. " Receiving the first approval for IL-6 use with newborns, is a significant step forward in helping clinicians confidently diagnose neonatal sepsis earlier and save more lives. ”Neonatal sepsis is an infection involving the bloodstream within the first four weeks of life and results in high rates of morbidity and mortality. Neonatal sepsis can initially present with subtle signs, but can rapidly progress to multisystem organ failure. Early detection and prompt intervention are essential to prevent severe and life-threatening complication...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news